H.C. Wainwright reiterates argenx stock buy rating on celiac drug data
H.C. Wainwright reiterated a Buy rating and $1,202 price target for argenx (ARGX) after positive Phase 2 trial results for FB102 in celiac disease. The stock is up 15% premarket. ARGX showed 70% revenue growth over the last year. Analysts have varied price targets and ratings for the company.
How this was made
The 30-second read
Why it matters
The Phase 2 readout validates the Forte Biosciences acquisition and could accelerate a Phase 3 launch, prompting analyst upgrades.
Market read
First‑report Phase 2 data is a material catalyst for ARGX and may influence peer biotech valuations.
What to watch
The trial size is modest and the endpoint is surrogate; market may overprice the result.
Background
ARGX is a $51.4 bn biotech focused on rare immune diseases. The FB102 trial targets celiac disease, a new indication for the company.
Ticker impact
ARGX reported positive Phase 2 data for FB102 in celiac disease, meeting primary endpoint and showing supportive effects.
upward pressure as the market prices in the trial success
First disclosure of statistically significant Phase 2 data; analysts have raised targets and reiterated buy ratings.
Market effects
Biotech sector may see broader optimism for rare‑disease programs.
U.S. biotech stocks could rally in early trade.
Positive data may attract foreign investors to U.S. biotech exposure.
Counterpoint
If Phase 3 fails, the current hype could reverse sharply.
Key entities
- companyARGX
Biotech firm developing FB102 for celiac disease.
- companyForte Biosciences
Acquired by ARGX, providing the FB102 asset.
